Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess the Safety and Efficacy of RP5063 in Subjects with an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder - REFRESH
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
100 Clinical Results associated with 5-HT1A receptor x 5-HT2A receptor x D4 receptor x D3 receptor x 5-HT6 receptor x 5-HT7 receptor x D2 receptor
Login to view more data
100 Translational Medicine associated with 5-HT1A receptor x 5-HT2A receptor x D4 receptor x D3 receptor x 5-HT6 receptor x 5-HT7 receptor x D2 receptor
Login to view more data
0 Patents (Medical) associated with 5-HT1A receptor x 5-HT2A receptor x D4 receptor x D3 receptor x 5-HT6 receptor x 5-HT7 receptor x D2 receptor
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.